TrialBMC cancer2023

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).

Naoki Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.